Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.

Literature DB >> 9756791

In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.

Abstract

The activities of a panel of currently available antibiotics and the investigational agents LY 333328, linezolid, CL 331,002, CL 329,998, moxifloxacin (BAY 12-8039), trovafloxacin, and quinupristin-dalfopristin against 274 clinical isolates of enterococci were determined. No vancomycin resistance or beta-lactamase production was observed. Except for 12 isolates (all non-Enterococcus faecalis) showing reduced susceptibility to quinupristin-dalfopristin (MIC, >/=4 microg/ml), the new agents exhibited promising in vitro antienterococcal activity.

Entities: Chemical Species

Mesh：

Substances：
Anti-Bacterial Agents

Year: 1998 PMID： 9756791 PMCID： PMC105933

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

15 in total

Review 1. The chemistry and biological profile of trovafloxacin.

Authors: K E Brighty; T D Gootz
Journal: J Antimicrob Chemother Date: 1997-06 Impact factor: 5.790

Review 2. The life and times of the Enterococcus.

Authors: B E Murray
Journal: Clin Microbiol Rev Date: 1990-01 Impact factor: 26.132

3. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds.

Authors: J C Barrière; D H Bouanchaud; J M Paris; O Rolin; N V Harris; C Smith
Journal: J Antimicrob Chemother Date: 1992-07 Impact factor: 5.790

4. Risk factors for acquiring ampicillin-resistant enterococci and clinical outcomes at a Canadian tertiary-care hospital.

Authors: A E McCarthy; G Victor; K Ramotar; B Toye
Journal: J Clin Microbiol Date: 1994-11 Impact factor: 5.948

5. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.

Authors: R T Testa; P J Petersen; N V Jacobus; P E Sum; V J Lee; F P Tally
Journal: Antimicrob Agents Chemother Date: 1993-11 Impact factor: 5.191

6. Dissociated resistance among fluoroquinolones.

Authors: K S Thomson; C C Sanders
Journal: Antimicrob Agents Chemother Date: 1994-09 Impact factor: 5.191

7. Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis.

Authors: D F Sahm; C Torres
Journal: J Clin Microbiol Date: 1988-02 Impact factor: 5.948

8. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.

Authors: R N Jones; H S Sader; M E Erwin; S C Anderson
Journal: Diagn Microbiol Infect Dis Date: 1995-02 Impact factor: 2.803

In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.

Review 1. The chemistry and biological profile of trovafloxacin.

Review 2. The life and times of the Enterococcus.

3. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds.

4. Risk factors for acquiring ampicillin-resistant enterococci and clinical outcomes at a Canadian tertiary-care hospital.

5. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.

6. Dissociated resistance among fluoroquinolones.

7. Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis.

8. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.

Review 9. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome.

10. Gene homogeneity for aminoglycoside-modifying enzymes in gram-positive cocci.

Review 1. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

2. Antibiotic resistance, efflux pump genes and virulence determinants in Enterococcus spp. from surface water systems.

3. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.

Review 4. A critical review of the fluoroquinolones: focus on respiratory infections.